Raynaud's phenomenon and digital necrosis induced by interferon-alpha

British Journal of Dermatology

Volumn 135, Issue 3, 1996, Pages 481-483

  Bachmeyer, C ^a   Farge, D ^a   Gluckman, E ^a   Miclea, J M ^a   Aractingi, S ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; CYTARABINE; HEPARIN; HYDROXYUREA; PROSTACYCLIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN NECROSIS;

EID: 0029819949     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb01521.x     Document Type: Article

References (14)

1. Conlon KC, Urba WJ, Smith JW et al. Exacerbation of symptoms of autoimmune diseases in patients receiving alpha-interferon therapy. Cancer 1990; 65: 2237-42.
2. Rönnblom LE, Aim GV, Oberg KE. Autoimmunity after α interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-83.
3. Sangster G, Kaye SB, Calman KC, Toy JL. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 1983; 19: 1657-8.
4. Roy V, Newland AC. Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon. Lancet 1988; i: 944-5.
5. Reid TJ, Lombardo FA, Redmond J et al. Digital vasculitis associated with interferon therapy. Am J Med 1992; 92: 702-3.
6. de Wolfe VG. Chronic occlusive arterial disease of the lower extremities. Cardiovascular Clin 1983; 13: 15-35.
7. Lämmle B, Wuillemin WA, Huber I et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency - a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
8. Vogelzang NJ, Bosi GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288-92.
9. Bellmunt J, Navarro M, Morales S, et al. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer 1990; 65: 303-9.
10. Cnudde F, Gharakhanian S, Luboinski J et al. Cutaneous local necrosis following interferon injection. Int J Dermatol 1991; 30: 147.
11. Orlow SJ, Friedman-Kien AE. Cutaneous ulcerations secondary to interferon alfa therapy of Kaposi's sarcoma. Arch Dermatol 1992; 128: 566.
12. Oeda E, Shinohara K. Cutaneous necrosis caused by injection of α-interferon therapy in a patient with chronic myelogeneous leukemia. Am J Hematol 1993; 44: 123-4.
13. Cozzolino F, Platt J, Torcia M et al. Interferon α and interleukin 2 synergistically enhance basic fibroblast growth factor and induce release promoting endothelial cell growth. J Clin Invest; 91: 2504-12.
14. Blaheta RA, Scholz M, Hailer NP et al. Adhesion and penetration properties of human lymphocytes acting on allogeneic endotbelial cells. Immunology 1994; 81: 538-45.